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Introduction: Systemic lupus erythematosus (SLE) is an autoim-
mune disease characterized by an acquired IL-2 deﬁciency in the
peripheral lymphoid organs and peripheral blood of murine and
human SLE (Humrich et al. 2010, von Spee-Mayer et al. 2015).
Kidney-inﬁltrating CD4+T cells play a crucial role in the progres-
sion of lupus nephritis (LN). However, the role of kidney- inﬁl-
trating T cells in the pathogenesis of LN is still not completely
understood. The aim of this study was to investigate whether an IL-
2 deﬁciency is also present in the inﬂamed kidney, thereby
contributing to an impaired intrarenal Treg function and renal
inﬂammation. Furthermore it was investigated if an IL-2-based
immunotherapy can directly act on intrarenal Treg and whether
this has consequences on the kidney inﬂammation.
Methods: Intrarenal CD4+ T cells phenotype of (NZBxNZW) F1
mice (NZB/W) with active LN was assessed and the in vitro IL-2
production of intrarenal CD4+CD44+ T cells were determined by
ﬂow cytometry. Furthermore, NZB/W mice were treated with re-
combinant IL-2 for a total of 31 days. Kidneys were histological
scored using the activity index (AI) and the intrarenal CD4+ T cell
phenotype was assessed in IL-2 treated mice compared to control
mice.
Results: Intrarenal Treg exhibit characteristic signs of IL-2 depri-
vation in parallel to a progressive hyperactivity of intrarenal Tcon
with disease progression. These Treg defects were associated with a
diminished production of IL-2 and an increased production of IFNg
by kidney-inﬁltrating Tcon. Furthermore, IL-2 therapy could in-
crease the frequency of intrarenal natural CD25+Helios+Treg,
strongly reduced the hyperactivity of intrarenal Tcon, ultimately
resulted in a reduced histological AI and prolonged the survival of
IL-2 treated lupus mice.
Conclusions: Our data indicate that on the one hand an IL-2 deﬁ-
ciency is also present in the inﬂamed kidney, thereby contributing
to renal inﬂammation. On the other hand, long term IL-2 treatment
is able to reduce hyperactivity of intrarenal Tcon and to diminish
kidney inﬂammation in lupus prone mice. This shows the close
relation between intrarenal IL-2 deﬁciency and resultant Treg de-
fects, the Tcon hyperactivity and the severity of LN. These results
also provide additional rationales for an IL-2 based immunotherapy
to treat patients with SLE, in particular with renal involvement.
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temic lupus erythematosus (SLE) that is usually treated with an
extended course of intravenous (IV) cyclophosphamide (CYC).
Given the side effects of high dose cyclophosphamide, we evaluated
the efﬁcacy of a course of low ﬁxed dose IV CYC prescribed as a
remission-inducing treatment, followed by (AZA) as a remission-
maintaining agent.
Methods: In this single center retrospective (january 2010 to
january 2014) clinical study, we evaluated 40 SLE patients with
proliferative glomerulonephritis who were given ﬁxed low dose IV
CYC regimen (500 mg 6 monthly pulses) followed by azathioprine
(AZA). AZA (2mg/kg/day) was started 2 weeks after the last CYC
injection. Oral prednisone was also given, beginning at a dose of
1 mg/kg per day and then tapering over a period of months to
alternate-day low dose maintenance therapy. Remission was deﬁned
as <10 red blood cells per high power ﬁeld, no cellular casts, and
proteinuria <1 g/day. Treatment failure was deﬁned as requiring
supplemental immunosuppression, doubling of the serum creati-
nine, or death. The renal relapse was deﬁned as doubling of the
urine protein-to-creatinine ratio or by an increase in the serum
creatinine to 1 & 1/2 times above normal.
Results: Mean serum creatinine at the time of initiating treatment
was 1.8 mg/dL. and mean urine protein excretion of 3.5 g/day. 7 of
the 40 patients (17.5%) experienced treatment failure, while rest of
all patients achieved remission (partial or complete) during induc-
tion phase. All seven treatment failure patients progressed to CKD,
as they could not afford other therapies/modalities available for
further treatment. Maintenance therapy with azathioprine was well
tolerated. 7 of 33 patients in remission developed renal ﬂares which
were treated successfully with pulse steroids followed by tapering
of steroids over 6 months.
Conclusions: Cyclophosphamide as an induction regimen followed
by maintenance with AZA is a viable and efﬁcient agent for the
treatment of proliferative lupus nephritis in a developing world
with economic constraints.
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Introduction: Lupus nephritis (LN) is one of the most serious
complications of systemic lupus erythematosus (SLE). Local MHC II
upregulation and a T cell rich inﬁltration suggest an antigen-spe-
ciﬁc immune response against kidney structures. Nevertheless, no
renal autoantigen is known at present.
Methods: The TCRß repertoire of peripheral blood and urinary T
cells was analyzed by TCRß chain sequencing and subsequent
sequence analysis. T cells from SLE Patients were stimulated with
different kidney lysates. Reactivity of T cells upon antigen stimu-
lation was tested using 3H+ Thymidin uptake in T cell libraries and
by detection of the activation markers CD40L and CD69 by ﬂow-
cytometry. Further renal candidate autoantigens were identiﬁedS21
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016based on the assumption that a corresponding autoantibody is
present and that the respective antigen is upregulated in the
inﬂamed kidney in LN. Known autoantibodies were retrieved from
Pubmed and expression levels of the respective targets were
retrieved from the GEO database.
Results: TCRß repertoire analysis demonstrated the presence of an
oligoclonal T cell population in the urine of patients with LN,
indicative of an antigen speciﬁc T cell response. However no T cell
response against lysates from healthy kidney tissue was detectable
in SLE patients, suggesting intact immune tolerance against normal
kidney tissue. Using an algorithm combining known targets of LN
associated autoantibodies and upregulation of these structures in
LN, 8 candidate renal autoantigens were identiﬁed. Of these auto-
antigens Vimentin was selected for a set of pilot experiments. Using
T cell libraries autoreactive CD4+ T cells reacting with Vimentin
were identiﬁed in 4 patients with active LN. In inactive SLE pa-
tients only few Vimentin reactive CD4+ T cells were observed
while no Vimentin speciﬁc T cells were detected in healthy
controls.
Conclusions: In LN there is no major breach of T cell immune
tolerance against “normal” kidney antigens. However CD4+ T cells
reactive with renal proteins with increased expression in LN are
detectable and presumably perpetuate the local renal inﬂammation.
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studied as potential therapeutic modulators of disease. CD362/
syndecan-2 is a heparan sulphate proteoglycan identiﬁed as a
functional marker for MSC isolation and therapeutic development.
These are present in both bone marrow derived MSC and umbilical
cord stromal cells. However, their therapeutic potential in diabetic
nephropathy is yet unclear. We speculated that a single dose of
CD362+ MSC could have beneﬁts in diabetic kidney disease.
Methods: LepRdb/db type 2 diabetic male mice were procured
from Taconic Biosciences (DK-8680 Ry, Denmark). At six weeks of
age uninephrectomy was performed to accelerate diabetic kidney
disease via increased hyperﬁltration. At 4 months of age only
proteinuric mice were randomized to either a single intravenous
dose of 250,000 CD362+ MSC or saline. 56 days later kidneys were
collected for immunostaining, ﬂow cytometry, ELISA and RT-PCR.
Proteinuria was assessed as albumin to creatinine ratio in spot urine
samples. Bio-distribution of MSC after injection was studied in
various organs at 4, 14, 28, and 56 days by detecting human DNA
(ALU) sequences in mouse tissues.
Results: LepRdb/db type 2 diabetic male mice showed increased
urine albumin/creatinine ratio, plasma creatinine, BUN levels and
decreased GFR levels versus baseline. This was associated with
diffuse glomerulosclerosis. Renal IL-6, TNF- , and iNOS mRNA
expression were signiﬁcantly increased in vehicle-treated mice.
CD362+ MSC-treated mice revealed a signiﬁcant reduction in glo-
merulosclerosis, albuminuria, plasma creatinine, BUN levels, and
showed a signiﬁcantly increased GFR. The markers of inﬂammation
were signiﬁcantly compared to vehicle-treated mice and reached
baseline level. Human DNA was not detectable in any organ tissue
at 4 days after injection or later.
Conclusions: Human CD362+MSC do not persist 4 days or more
upon injection in diabetic mice. Nevertheless, CD362+ MSC were
able to protect the type 2 diabetic mice with kidney disease through
modulation of inﬂammation. Our studies were based on single MSC
injections, as the MSC did not persist in the tissue, repetitive in-
jections might be even more effective. We conclude that a single
injection of CD362+ MSC can have beneﬁcial effects on diabetic
nephropathy via a systemic effect.Kidney International Reports (2016) 1, S1–S22
